Mark Curtis
Mark is a Business Development Analyst at the Centre for Commercialization of Regenerative Medicine (CCRM), where he collaborates with the team to help evaluate the commercial potential of regenerative medicine and cell therapy technologies. He began his career at Princess Margaret Hospital studying cellular reprogramming of human skin cells. Following this project, he left the laboratory and took on a role with Bloom Burton & Co., a healthcare-focused investment dealer. While there he supported the advisory team in carrying out scientific diligence on early-stage biotechnology companies. Prior to joining CCRM he was a consultant to Stem Cell Therapeutics, a Toronto-based biotechnology company focused on developing therapeutics targeting cancer stem cells. Mark received a Master’s degree from the University of New South Wales in Sydney, where he studied the directed differentiation of embryonic stem cells, and a Bachelor’s degree in Biology, from Queen’s University. Follow Mark on Twitter @markallencurtis
Posts by: Mark
Regenerative Medicine Deal Review: April
. Welcome to your deal review for the month of April. There is no update yet on the fate of the Cellular Dynamics International/Fujifilm deal, but it appears that CDI made some effort to solicit offers from alternative bidders. Aduro made headlines, though, closing a *$136 million initial public offering (IPO) and opening on its […]
Cracking the code of pancreatic development: beta cells from iPS cells
. After several years of intense systematic research, and toiling with a differentiation protocol, Dr. Doug Melton, and his lab at Harvard University, finally decoded the sequence of genes that needs to be activated to yield mature, insulin-producing beta cells in vitro. While a few investigators have managed to get in the vicinity and generate […]
Regenerative Medicine Deal Review: March
. Welcome to your deal review for the month of March. Cellular Dynamics threw shareholders for a loop after making a seemingly hasty decision to sell the company off to Fujifilm in a $307* million deal. Merck and synthetic biology specialist Intrexon announced a mammoth CAR-T deal, valued at nearly a billion dollars. Kite Pharma […]
Regenerative Medicine Deal Review: May
. Welcome to your deal review for the month of May. Juno Therapeutics was active, forming a strategic research collaboration with Fate Therapeutics and acquiring Stage Cell Therapeutics. Adaptimmune decided it would take advantage of the ongoing initial public offering (IPO) window and went public to raise net proceeds of just under $180 million*. NeoStem […]